Tetsuya Mishima
Directeur/Bestuurslid bij Anaeropharma Science, Inc.
Oorsprong van het eerstegraads netwerk van Tetsuya Mishima
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan.
5
| Holding Company | Biotechnology | 5 |
CellGenTech, Inc.
CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Watervein Partners KK
Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi.
3
| Private Company | Investment Managers | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Tetsuya Mishima via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
University of Tokyo | College/University | Doctorate Degree Undergraduate Degree | |
Citigroup Global Markets Japan, Inc.
Citigroup Global Markets Japan, Inc. Investment Banks/BrokersFinance Citigroup Global Markets Japan, Inc. (CGM-JP) is a wholly-owned broker/dealer subsidiary of Citigroup Japan Holdings GK, ultimately held by Citigroup, Inc. (NYSE: C) in the US. Previously known as Nikko Citigroup Ltd., the firm was founded in 1999 as a joint venture between US-based Citigroup and Nikko Securities, based in Japan. Headquartered in Tokyo, CGM-JP provides brokerage services to governmental institutions, financial institutions, multinational corporations and institutional investors. Their sales and trading, distribution and research capabilities span a broad range of asset classes, currencies, sectors and products including equities, commodities, credit, futures, foreign exchange (FX), emerging markets, G10 rates, municipals, prime finance and securitized markets. | Investment Banks/Brokers | Analyst-Equity | |
Agra Corp.
Agra Corp. Packaged SoftwareTechnology Services Agra Corp. develops and sells data management and analysis software. It specializes in data integration and data mapping solutions. It also offers visualization and virtual data consolidation services. The company was founded by Hiroshi Tange in March 2008 and is headquartered in Tokyo, Japan. | Packaged Software | Director/Board Member | |
EISAI CO., LTD. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Pharmaceuticals: Major | President | |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Pharmaceuticals: Major | Founder | |
KinoPharma, Inc.
KinoPharma, Inc. Pharmaceuticals: MajorHealth Technology KinoPharma, Inc. manufactures pharmaceutical products. It deals with the research and development of protein phosphorylation enzyme and low molecular clinical drugs. The company was founded by Masatoshi Hagiwara on April 11, 2005 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Chief Executive Officer | |
NISSUI PHARMACEUTICAL CO., LTD. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Quantum Biosystems, Inc.
Quantum Biosystems, Inc. BiotechnologyHealth Technology Quantum Biosystems, Inc. is a holding company that develops single-molecule DNA sequencers. It develops and commercializes sequencers based on quantum mechanics. The company was founded by Toshihiko Honkura and Masateru Taniguchi on January 7, 2013 and is headquartered in Osaka, Japan. | Biotechnology | Director/Board Member | |
Megakaryon Corp.
Megakaryon Corp. Medical/Nursing ServicesHealth Services Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan. | Medical/Nursing Services | Director/Board Member | |
GLOBIS University | College/University | Masters Business Admin | |
SCOHIA PHARMA, Inc.
SCOHIA PHARMA, Inc. Miscellaneous Commercial ServicesCommercial Services SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Japan | 13 |
Verenigde Staten | 2 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Finance | 3 |
Technology Services | 2 |
Health Services | 2 |
Operationeel
Director/Board Member | 13 |
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
President | 3 |
Private Equity Investor | 3 |
Sterkste connecties
- Beurs
- Insiders
- Tetsuya Mishima
- Bedrijfsconnecties